Sevilla

• A Multi-centered, Double-blind, Randomized, Placebo-controlled Study of TEV-56286 for the Treatment of Multiple System Atrophy Recruiting
  2023-505320-54-00 4 2025-01-30 Multiple System Atrophy
• A study describing the efficacy and safety of belimumab administered subcutaneously in adult participants with early systemic lupus erythema … Recruiting
  2023-509146-35-00 6 2025-01-30 Systemic Lupus Erythematosus
• Fast-Track Therapeutic Model in Complicated Acute Appendicitis Recruiting
  2025-520777-39-00 6 2025-01-29 Complicated acute appendicitis
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting
  2023-508234-34-00 4 2025-01-27 Crohn's disease
• IMMUNOTHERAPY WITH DIFFERENTIATED T CELLS, ADULTS, AUTOLOGOUS, FROM PERIPHERAL BLOOD, SELECTED BY CD62L EXPRESSION, EXPANDED AND TRANSDUCED … Recruiting
  2024-519790-19-00 7 2025-01-24 Relapsed/refractory large B-cell non-Hodgkin lymphoma, mantle cell lym
• Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc … Recruiting
  2024-513852-13-00 5 2025-01-20 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
• COLCHICINE IN SECONDARY PREVENTION OF VASCULAR EVENTS AND RENAL PROGRESSION IN PATIENTS WITH MODERATE CHRONIC RENAL DISEASE Recruiting
  2023-505868-11-00 5 2025-01-17 CHRONIC RENAL DISEASE
• A study to evaluate the efficacy and safety of frexalimab, brivekimig or rilzabrutinib in participants aged 16 to 75 years with primary foca … Recruiting
  2024-511775-15-00 4 2025-01-17 Immune system diseases
• Efecto de la inmunoterapia en pacientes con cáncer de pulmón de células no pequeñas oligometastásico (número limitado de metástasis) después … Recruiting
  2023-508741-40-00 10 2025-01-14 Non-small cell lung cancer
• Efficacy and safety of prednisone in the treatment of idiosyncratic hepatotoxicity Recruiting
  2024-513004-33-00 4 2025-01-14 Hepatotoxicity
• Role of Pancreatic Enzyme Replacement Therapy (PERT) (Creon®) for Pancreatic Exocrine Insufficiency (PEI) after Pancreatic Surgery Recruiting
  2024-512798-29-00 5 2025-01-07 Male and female patients aged ≥ 18 to ≤ 85 years with a total pancreat
• Oral antimicrobial treatment vs. outpatient parenteral for infective endocarditis Recruiting
  2024-519969-21-00 6 2025-01-01 Infective endocarditis
• Evaluating how well and how safely Alisertib works with hormone therapy in treating patients with breast cancer that has come back or spread … Recruiting
  2024-511497-79-00 4 2024-12-30 Hormone receptor positive (HR+), human epidermal growth factor recepto
• A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 65 years with alcohol-re … Recruiting
  2024-511596-15-00 4 2024-12-26 Liver Diseases, Alcoholic
• Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Recruiting
  2024-511188-26-00 5 2024-12-20 Relapsed/refractory multiple myeloma in patients who have received 1 t
• PROMETEO-HG Recruiting
  2024-516561-37-01 5 2024-12-19 Metabolic Associated Fatty Liver Disease with prediabetes.
• A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting
  2023-508813-18-00 4 2024-12-18 Refractory Focal Onset Epilepsy
• Acalabrutinib Monotherapy vs Investigator’s Choice of Treatment in Patients with Chronic Lymphocytic Leukaemia and Moderate to Severe Cardia … Recruiting
  2023-510147-37-00 6 2024-12-18 Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairmen
• Treatment with a single drug that prevents blood clot formation followed by an anticoagulant drug in patients with irregular heartbeat who h … Recruiting
  2023-509717-36-00 5 2024-12-16 AF patients who have undergone successful PCI
• Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis (SchizOMICS) Recruiting
  2024-516768-28-00 6 2024-12-16 Schizophrenia
• A Phase 3 efficacy and safety study of fosmanogepix for the treatment of adult participants with candidemia and/or invasive candidiasis. Recruiting
  2022-500455-23-00 5 2024-12-11 Candidemia
• This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP. Recruiting
  2023-507351-29-00 5 2024-12-03 Alzheimer's Disease Psychosis
• A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys … Recruiting
  2023-508960-31-00 5 2024-12-03 Metastatic HER2-positive breast cancer
• A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting
  2023-508191-11-00 5 2024-11-28 Systemic lupus erythematosus (SLE)

Showing 529–552 of 1,630 trials